bromodeoxyuridine has been researched along with Coronary Artery Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbot, SE; Blake, DR; Mills, PG; Thorne, SA; Winyard, PG | 1 |
| Baur, R; Fischer, R; Hombach, V; Koenig, W; Osswald, M; Susa, M; Voglic, S; Voisard, R | 1 |
2 other study(ies) available for bromodeoxyuridine and Coronary Artery Disease
| Article | Year |
|---|---|
Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells.
Topics: Bromodeoxyuridine; Cell Movement; Chromium Radioisotopes; Coronary Artery Disease; Coronary Vessels; Endothelium, Vascular; Humans; In Vitro Techniques; Lipoproteins, LDL; Muscle, Smooth, Vascular; Oxidation-Reduction | 1996 |
Aspirin (5 mmol/L) inhibits leukocyte attack and triggered reactive cell proliferation in a 3D human coronary in vitro model.
Topics: Aspirin; Blotting, Northern; Bromodeoxyuridine; CD4-Positive T-Lymphocytes; Cell Adhesion; Cell Division; Cells, Cultured; Chemotaxis; Coronary Artery Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Flow Cytometry; Humans; In Vitro Techniques; Intercellular Adhesion Molecule-1; Leukocytes; Monocytes; Muscle, Smooth, Vascular; RNA, Messenger; Tumor Necrosis Factor-alpha | 2001 |